Literature DB >> 32343773

Trastuzumab: Weighing the Benefits and the Risks.

Anne H Blaes1, Chau Dang2.   

Abstract

Entities:  

Year:  2020        PMID: 32343773      PMCID: PMC7824039          DOI: 10.1093/jnci/djaa055

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  16 in total

1.  Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.

Authors:  Heikki Joensuu; Judith Fraser; Hans Wildiers; Riikka Huovinen; Päivi Auvinen; Meri Utriainen; Paul Nyandoto; Kenneth K Villman; Päivi Halonen; Helena Granstam-Björneklett; Lotta Lundgren; Liisa Sailas; Taina Turpeenniemi-Hujanen; Minna Tanner; Jeffrey Yachnin; Diana Ritchie; Oskar Johansson; Teppo Huttunen; Patrick Neven; Peter Canney; Vernon J Harvey; Pirkko-Liisa Kellokumpu-Lehtinen; Henrik Lindman
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

2.  Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.

Authors:  P Conte; A Frassoldati; G Bisagni; A A Brandes; M Donadio; O Garrone; F Piacentini; L Cavanna; F Giotta; M Aieta; V Gebbia; A Molino; A Musolino; A Ferro; R Maltoni; S Danese; C Zamagni; A Rimanti; K Cagossi; A Russo; P Pronzato; F Giovanardi; G Moretti; L Lombardo; A Schirone; A Beano; L Amaducci; E A Bajardi; R Vicini; S Balduzzi; R D'Amico; V Guarneri
Journal:  Ann Oncol       Date:  2018-12-01       Impact factor: 32.976

3.  Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

Authors:  D Mavroudis; E Saloustros; N Malamos; S Kakolyris; I Boukovinas; P Papakotoulas; N Kentepozidis; N Ziras; V Georgoulias
Journal:  Ann Oncol       Date:  2015-05-01       Impact factor: 32.976

4.  11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Authors:  David Cameron; Martine J Piccart-Gebhart; Richard D Gelber; Marion Procter; Aron Goldhirsch; Evandro de Azambuja; Gilberto Castro; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Nedal Al-Sakaff; Sabine Lauer; Eleanor McFadden; Brian Leyland-Jones; Richard Bell; Mitch Dowsett; Christian Jackisch
Journal:  Lancet       Date:  2017-02-17       Impact factor: 79.321

5.  NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Authors:  William J Gradishar; Benjamin O Anderson; Ron Balassanian; Sarah L Blair; Harold J Burstein; Amy Cyr; Anthony D Elias; William B Farrar; Andres Forero; Sharon Hermes Giordano; Matthew P Goetz; Lori J Goldstein; Steven J Isakoff; Janice Lyons; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Meena S Moran; Ruth M O'Regan; Sameer A Patel; Lori J Pierce; Elizabeth C Reed; Kilian E Salerno; Lee S Schwartzberg; Amy Sitapati; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; George Somlo; Melinda Telli; John H Ward; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

6.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Authors:  Sara M Tolaney; William T Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Ann H Partridge; Hao Guo; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  N Engl J Med       Date:  2015-01-08       Impact factor: 91.245

7.  Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada.

Authors:  Moira Rushton; Isac Lima; Meltem Tuna; Chris Johnson; Josee Ivars; Kathy Pritchard; Steven Hawken; Susan Dent
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

8.  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Authors:  Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; George Sledge; Charles E Geyer; Silvana Martino; Priya Rastogi; Julie Gralow; Sandra M Swain; Eric P Winer; Gerardo Colon-Otero; Nancy E Davidson; Eleftherios Mamounas; Jo Anne Zujewski; Norman Wolmark
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

9.  Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Authors:  Lisa A Carey; Donald A Berry; Constance T Cirrincione; William T Barry; Brandelyn N Pitcher; Lyndsay N Harris; David W Ollila; Ian E Krop; Norah Lynn Henry; Douglas J Weckstein; Carey K Anders; Baljit Singh; Katherine A Hoadley; Michael Iglesia; Maggie Chon U Cheang; Charles M Perou; Eric P Winer; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

10.  Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.

Authors:  Laura M Spring; Geoffrey Fell; Andrea Arfe; Lorenzo Trippa; Aditya Bardia; Chandni Sharma; Rachel Greenup; Kerry L Reynolds; Barbara L Smith; Brian Alexander; Beverly Moy; Steven J Isakoff; Giovanni Parmigiani
Journal:  Clin Cancer Res       Date:  2020-02-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.